Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
Yamai T, Ikezawa K, Kawamoto Y, Hirao T, Higashi S, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Takada R, Nakabori T, Uehara H, Ohkawa K. Yamai T, et al. Among authors: daiku k. Curr Oncol. 2022 Apr 11;29(4):2644-2649. doi: 10.3390/curroncol29040216. Curr Oncol. 2022. PMID: 35448190 Free PMC article.
Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer.
Ikezawa K, Kiyota R, Takada R, Daiku K, Maeda S, Imai T, Abe Y, Kai Y, Yamai T, Fukutake N, Nakabori T, Ashida R, Uehara H, Tabuchi T, Katayama K, Ohkawa K. Ikezawa K, et al. Among authors: daiku k. JGH Open. 2021 May 10;5(6):679-685. doi: 10.1002/jgh3.12555. eCollection 2021 Jun. JGH Open. 2021. PMID: 34124386 Free PMC article.
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer.
Takada R, Ikezawa K, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Yamai T, Fukutake N, Nakabori T, Uehara H, Ashida R, Akita H, Takahashi H, Teshima T, Ohkawa K. Takada R, et al. Among authors: daiku k. Cancers (Basel). 2021 Sep 21;13(18):4733. doi: 10.3390/cancers13184733. Cancers (Basel). 2021. PMID: 34572960 Free PMC article.
Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
Yamai T, Ikezawa K, Hiraga E, Kawamoto Y, Hirao T, Higashi S, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Takada R, Nakabori T, Fukutake N, Uehara H, Fujita M, Ohkawa K. Yamai T, et al. Among authors: daiku k. PLoS One. 2022 Mar 1;17(3):e0264653. doi: 10.1371/journal.pone.0264653. eCollection 2022. PLoS One. 2022. PMID: 35231078 Free PMC article.
14 results